Kevin Lafferty

Father of three, husband and family man.

[Kevin Lafferty @Lafferty_KevinF]

@JamesPalmerTV @JasonKelce prediction. He retires at the end of 2023 . In 2024 the Chiefs find themselves in need of more depth on the O lines. So Jason gets the call from his old coach Andy Reid and comes out of retirement for a few games to play with @tkelce.

[Kevin Lafferty @Lafferty_KevinF]

Come join my team. We are looking for an experienced sales professional to support our customers on the west coast. Message me if you would like to discuss or follow the link below to see more details and apply. https://t.co/OETosIzcwj

[Kevin Lafferty @Lafferty_KevinF]

Quidel is continuing to grow! We have multiple R&D Scientist positions available ranging from Associate Scientist to Senior Scientist. Take a look: #Quidel #hiring #researchanddevelopment #career

https://t.co/cqJ0ZLwfDv

[Kevin Lafferty @Lafferty_KevinF]

@MelindaCoughlan We have a distributor in Australia, you can message me for their details

[Kevin Lafferty @Lafferty_KevinF]

Our Expanded Complement Multiplex is now available! 17 Complement Proteins on two Customizable Panels. Thousands of Options, Vast Amount of Data. #Complementsystem #Complement #Quidel

[Kevin Lafferty @Lafferty_KevinF]

@MelindaCoughlan we partnered with @quansysbio using their Chemiluminescent imager, Q-view LS.

[Kevin Lafferty @Lafferty_KevinF]

#AMY101 Continues to move forward in Covid-19 trials!

[Amyndas Pharmaceuticals @Amyndas]

To #AMY101 θα δοκιμαστεί σε COVID-19 ασθενείς σε 6 νοσοκομεία της Ελλάδος https://t.co/RrtDZgYPb3

[Kevin Lafferty @Lafferty_KevinF]

Research into the role of #complementsystem in #covid19 continues. Congrats to #amyndas on your continued success with Amy-101. https://t.co/pzV8pI8VnB

[John D. Lambris, Ph.D. @LambrisJD]

Check out our new study comparing C3 inhibition with C5 blockade in #COVID19: our early clinical findings offer important insight into the differential mechanistic basis of C3 & C5 inhibition and support a broader therapeutic profile of #AMY101 in COVID-19 #thromboinflammation

[Kevin Lafferty @Lafferty_KevinF]

#ComplementSystem #Quidel https://t.co/qVtuHTlz6V

[John D. Lambris, Ph.D. @LambrisJD]

Delighted to join in the global efforts to combat this unprecedented health challenge: Our third-generation C3 inhibitor #AMY101, safely delivered to a #COVID19 patient, shows early clinical benefit attenuating lung inflammation!

[John D. Lambris, Ph.D. @LambrisJD]

Excited to see the PEGylated version of the #compstatin analog discovered in my lab @Penn completing a Phase II trial in #AMD @ApellisPharma #C3inhibitor #peptide https://t.co/C9qgjO9Xhz

[Kevin Lafferty @Lafferty_KevinF]

I'm looking forward to the Third Complement Therapeutics meeting in Boston the November! #ComplementSystem #ComplementTherapeutics https://t.co/meUlKYofHR

[Kevin Lafferty @Lafferty_KevinF]

PTX3 levels rise quickly in response to infections and perform a regulatory role on inflammation, complement activation, cell extravasation and pathogen recognition by myeloid cells. #innateimmunity #ComplementSystem #sepsis https://t.co/pF5eAVqiHi

[Kevin Lafferty @Lafferty_KevinF]

Great Opportunity to join the Quidel team! https://t.co/vqZ0TXBtUh

[Kevin Lafferty @Lafferty_KevinF]

@mckfrank we can't all look as good as you!

[Kevin Lafferty @Lafferty_KevinF]

Venom from funnel web spider could reduce brain daamage after a stroke!https://t.co/TSVIeVAD3z

[Wendy Kovitz @STEAMstreamer]

Why the #complementsystem is set to shine https://t.co/c7om4DnN6A

[Kevin Lafferty @Lafferty_KevinF]

@AVEMalvern is offering a free months rent! Check it out, great location and amenities. https://t.co/MgPjJBHwdd